Promore Pharma in Brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s project ropocamptide has been investigated in a clinical Phase II trial and have showed a significant medical effectiveness combined  with  a very strong safety profile since the product is based on an endogeneous substance that is administered locally. The company is listed on Nasdaq First North Growth Market.

Promore Pharma’s product candidate ropocamptide is based on an endogeneous peptide that is derived from a sequence of human innate immune system. The product is aimed for local application and exerts its action in the surrounding tissue.  Ropocamptide has a strong safety profile since it is quickly degraded in the blood stream and are therefore unlikely to contribute to severe systemic adverse events. The results from prior clinical studies are very promising when it comes to tolerability and safety as well as efficacy. The product candidate is protected by several international patent families offering protection until 2030 and longer. The patents provide protection in several dimensions, such as therapeutic use, formulation and dosage ranges.

Ropocamptide has the potential of becoming a first-in-category therapeutics for several patient groups, segments where patients experience reduced mobility, lowered quality-of-life and social stigma.

Promore Pharma is a small and cost-effective company without its own laboratories or research facilities, using a network of high-quality contract research organizations and contract manufacturing organizations. The company has experienced advisors in all critical aspects of the strategic planning process, including product development, regulatory affairs, design and execution of clinical trials.

Promore Pharma’s overall strategy is to take the product candidates through clinical development to market authorization or to a point when a license agreement, alternatively a commercial deal with a larger pharmaceutical company with global presence can be realized. Such transactions may include out-partnering/licensing, strategic partnerships, joint ventures or asset sales.